Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study GroupTimothy R. Rebbeck, Barbara Weber, Tara M. Friebel et al.|Journal of Clinical Oncology|2005Cited by 406
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330
Impact of <i>BRCA1</i>/<i>BRCA2</i> Counseling and Testing on Newly Diagnosed Breast Cancer PatientsMarc D. Schwartz, Claudine Isaacs, Caryn Lerman et al.|Journal of Clinical Oncology|2004Cited by 250
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast CancerDouglas Yee, Minetta C. Liu, Angela DeMichele et al.|JAMA Oncology|2020Cited by 225